#United States #Carlsbad #Tyra Biosciences #FGFR Biology #Dabogratinib

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Developments

On August 14, 2025, Tyra Biosciences, Inc. (Nasdaq: TYRA), a pioneering clinical-stage biotechnology firm, announced its financial performance for the second quarter ending June 30, 2025. The report highlights the company's significant progress in developing precision therapies targeting Fibroblast Growth Factor Receptor (FGFR) biology, particularly in the treatment of bladder cancer and skeletal disorders.

According to Todd Harris, the company's CEO, Tyra Biosciences is on the verge of a breakthrough in changing the treatment landscape for bladder cancer and skeletal dysplasia through its FGFR3-targeted drug, dabogratinib (formerly TYRA-300). Harris remarked, "With BEACH301 now open for enrollment and SURF302 making strides within the intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) segment, dabogratinib is pivotal in harnessing FGFR3 selectivity and sensitivity."

Financial Overview

In the financial report, Tyra Biosciences revealed that it holds cash, cash equivalents, and marketable securities totaling $296.3 million, ensuring operational sustainability through at least 2027. The company also reported research and development (R&D) expenses of $24.3 million for the quarter, up from $18.0 million in the same period last year. The increase corresponds with ongoing enrollment and startup cost for several clinical trials including SURF302 and BEACH301.

The company's general and administrative (G&A) expenses also rose to $7.1 million, reflecting higher personnel-related costs. For the second quarter, Tyra recorded a net loss of $28.1 million, compared to $18.7 million in the previous year. The rise in losses can be attributed to expanded clinical trials and increased operational expenditures.

Recent Clinical Developments

Dabogratinib (TYRA-300)

Dabogratinib is an oral FGFR3-selective inhibitor currently being evaluated for IR NMIBC and achondroplasia (ACH). The drug has successfully dosed its first patient under the SURF302 Phase 2 clinical study. This trial aims to determine the safety and efficacy of dabogratinib in patients with FGFR3-altered low-grade IR NMIBC, focusing on the complete response rate after three months of treatment. Additionally, the BEACH301 study is currently advancing, targeting children aged 3 to 10 diagnosed with achondroplasia.

TYRA-430 and TYRA-200

The TYRA-430 study continues in Phase 1, examining its use in patients with FGF19+/FGFR4-driven advanced hepatocellular carcinoma (HCC). Dosing remains on track as the study progresses. Meanwhile, TYRA-200 aims to address metastatic intrahepatic cholangiocarcinoma while completing its Phase 1 SURF201 study, which focuses on understanding the maximum tolerated dose and initial safety of the treatment.

SNÅP Precision Medicine Platform

Tyra's proprietary SNÅP platform remains an integral part of its drug development mechanism, allowing for rapid and precise drug designs aimed at oncological and genetically defined conditions. This platform enhances Tyra's capacity to develop therapies effectively and accurately, addressing significant unmet medical needs.

Outlook and Milestones

Looking ahead, Tyra anticipates the dosing of the first child in the BEACH301 trial by the third quarter of 2025, as well as releasing initial data from the SURF302 trial in the first half of 2026.

Tyra Biosciences stands at a critical juncture, equipped with a strong financial foundation and an innovative approach to precision medicine. As the company advances its trial stages and gathers data, it could reshape treatment protocols for bladder cancer and related conditions in the near future.